Yan Sun

Ms. Yan Sun

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2023 in Scientia Horticulturae
Verified
Journal Article
Closed access
JZJing Zhou
Jing Zhou
Feng AnFeng An
Feng An
YSYan Sun
Yan Sun
RGRuiquan Guo
Ruiquan Guo
LPLiuyi Pan
Liuyi Pan
Yuliang CaiYuliang Cai
Yuliang Cai

31 October 2020 in Genes
Verified
Journal Article
Open access
PDF file
YSYan Sun
Yan Sun
JGJiajia Gao
Jiajia Gao
JZjing zong
jing zong
YZyan zhao
yan zhao
YSYULIN SUN
YULIN SUN
XZXiaohang Zhao
Xiaohang Zhao
Esophageal squamous cell carcinoma (ESCC) is one of the most lethal gastrointestinal malignancies due to its characteristics of local invasion and distant metastasis. Purine element binding protein α (PURα) is a DNA and RNA binding protein, and recent studies have showed that abnormal expression of PURα is associated with the progression of some tumors, but its oncogenic function, especially in ESCC progression, has not been determined. Based on the bioinformatic analysis of RNA-seq and ChIP-seq data, we found that PURα affected metabolic pathways, including oxidative phosphorylation and fatty acid metabolism, and we observed that it has binding peaks in the promoter of mitochondrial phosphoenolpyruvate carboxykinase (PCK2). Meanwhile, PURα significantly increased the activity of the PCK2 gene promoter by binding to the GGGAGGCGGA motif, as determined though luciferase assay and ChIP-PCR/qPCR. The results of Western blotting and qRT-PCR analysis showed that PURα overexpression enhances the protein and mRNA levels of PCK2 in KYSE510 cells, whereas PURα knockdown inhibits the protein and mRNA levels of PCK2 in KYSE170 cells. In addition, measurements of the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) indicated that PURα promoted the metabolism of ESCC cells. Taken together, our results help to elucidate the molecular mechanism by which PURα activates the transcription and expression of PCK2, which contributes to the development of a new therapeutic target for ESCC.